Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide
Diabetes Care
.
2018 Sep;41(9):e133-e135.
doi: 10.2337/dc18-0999.
Epub 2018 Jul 12.
Authors
Jakob Schöllhammer Knudsen
1
,
Reimar Wernich Thomsen
2
,
Anton Pottegård
3
,
Filip Krag Knop
4
5
,
Henrik Toft Sørensen
2
Affiliations
1
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark jsk@clin.au.dk.
2
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
3
Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark.
4
Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, University of Copenhagen, Gentofte, Denmark.
5
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
PMID:
30002200
DOI:
10.2337/dc18-0999
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't